KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Sales and Divestitures (2016 - 2025)

Sarepta Therapeutics has reported Gains from Sales and Divestitures over the past 16 years, most recently at $33215.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 25.02% year-over-year to $33215.0; the TTM value through Dec 2025 reached $33215.0, down 25.02%, while the annual FY2025 figure was $33215.0, 25.02% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $33215.0 at Sarepta Therapeutics, down from $38050.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $644614.0 in Q4 2023 and troughed at $33215.0 in Q4 2025.
  • A 5-year average of $200170.5 and a median of $70880.0 in 2024 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 230.72% in 2021 and later crashed 93.13% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $276980.0 in 2021, then surged by 40.72% to $389761.0 in 2022, then skyrocketed by 65.39% to $644614.0 in 2023, then crashed by 93.13% to $44300.0 in 2024, then decreased by 25.02% to $33215.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for SRPT at $33215.0 in Q4 2025, $38050.0 in Q3 2025, and $38050.0 in Q2 2025.